PubRank

C Loveday

Author PubWeight™ 105.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000 7.81
2 Prevalence of antibodies to human immunodeficiency virus, gonorrhoea rates, and changed sexual behaviour in homosexual men in London. Lancet 1987 7.71
3 The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections. Department of Health (England). J Hosp Infect 2001 4.95
4 Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995 4.60
5 Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA 1998 4.42
6 The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995 2.95
7 Hepatitis C virus: evidence for sexual transmission. BMJ 1991 2.50
8 Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet 1995 2.17
9 A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol 1992 2.15
10 HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet 1997 1.98
11 British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003 1.94
12 Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 1996 1.94
13 Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001 1.86
14 Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 1996 1.77
15 Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996 1.75
16 HIV results in the frame. Results confirmed. Nature 1995 1.69
17 Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Virol 1991 1.68
18 Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999 1.65
19 Attitudes of cardiothoracic surgeons in the UK to human immunodeficiency virus. Br J Surg 1992 1.38
20 Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 2000 1.24
21 The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses 1995 1.18
22 Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 2001 1.18
23 Neuropsychological profile of young adults with spina bifida with or without hydrocephalus. J Neurol Neurosurg Psychiatry 2004 1.16
24 In vivo effects of cellulose sulphate on plasma kininogen, complement and inflammation. Br J Pharmacol 1971 1.14
25 Changes in intra-vascular complement and anti-treponemal antibody titres preceding the Jarisch-Herxheimer reaction in secondary syphilis. Clin Exp Immunol 1976 1.12
26 Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Res Hum Retroviruses 2000 1.09
27 Interventions to prevent vertical transmission of HIV-1: effect on viral detection rate in early infant samples. AIDS 2000 1.06
28 Adherence to antiretroviral therapy: appropriate use of self-reporting in clinical practice. HIV Clin Trials 2001 1.05
29 Course of viral load throughout HIV-1 infection. J Acquir Immune Defic Syndr 2000 1.05
30 HIV-1 plasma viraemia quantification: a non-culture measurement needed for therapeutic trials. J Virol Methods 1993 1.03
31 Intrinsic activation of plasma kinin formation and complement. Int Arch Allergy Appl Immunol 1973 0.99
32 Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS 2001 0.97
33 HIV type 1 sequence subtype G transmission from mother to infant: failure of variant sequence species to amplify in the Roche Amplicor Test. AIDS Res Hum Retroviruses 1995 0.96
34 The use of HIV resistance assays--random or randomised? Sex Transm Infect 1999 0.96
35 Diurnal patterns of salivary cortisol across the adolescent period in healthy females. Psychoneuroendocrinology 2008 0.95
36 Effect of cellulose sulphate on serum complement. Br J Pharmacol 1970 0.94
37 The diurnal cortisol cycle and cognitive performance in the healthy old. Int J Psychophysiol 2010 0.93
38 Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group. AIDS 1995 0.91
39 Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage. Sex Transm Infect 1998 0.91
40 Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents. Antimicrob Agents Chemother 2001 0.89
41 Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. J Infect Dis 2000 0.87
42 Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia. J Infect Dis 2000 0.86
43 From persistent generalised lymphadenopathy to AIDS: who will progress? Br Med J (Clin Res Ed) 1987 0.86
44 Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation. Br J Pharmacol 1973 0.86
45 In vivo HIV-1 replicative capacity in early and advanced infection. AIDS 1999 0.86
46 Storage and preservation of whole blood samples for use in detection of human immunodeficiency virus type-1 by the polymerase chain reaction. J Virol Methods 1992 0.85
47 Activation of arginine and tyrosine esterase in serum from patients with hereditary angio-oedema. Br J Pharmacol 1972 0.84
48 The neuropsychology of normal pressure hydrocephalus (NPH). Br J Neurosurg 2005 0.83
49 Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy. J Clin Microbiol 1998 0.82
50 Effects of salicylates on blood changes in mycoplasma arthritis in rats. Br J Pharmacol 1973 0.82
51 Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine. AIDS 2000 0.81
52 Quantitative differences in the distribution of zidovudine resistance mutations in multiple post-mortem tissues from AIDS patients. J Med Virol 1998 0.81
53 A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators. J Acquir Immune Defic Syndr 2005 0.80
54 Non-traumatic blood collection from rat tail vessels. Application in Mycoplasma arthritidis. Br J Pharmacol 1971 0.80
55 Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine. AIDS 1990 0.80
56 The neuromuscular blocking action of suxamethonium in the anaesthetised rat. Arch Int Pharmacodyn Ther 1969 0.79
57 HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries. Acta Dermatovenerol Alp Pannonica Adriat 2010 0.79
58 Changes in intravascular kininogen during the Jarisch-Herxheimer reaction in secondary syphilis. Br J Vener Dis 1982 0.79
59 HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis and clinical management. J Med Virol 1997 0.78
60 Long-latency event-related potentials in asymptomatic human immunodeficiency virus type 1 infection. Ann Neurol 1994 0.78
61 The prevalence of non-B subtype HIV-1 in a London HIV/AIDS outpatient clinic. AIDS 1999 0.78
62 Use of polymerase chain reaction and quantitative antibody tests in children born to human immunodeficiency virus-1-infected mothers. J Med Virol 1995 0.78
63 'Naïve' and 'memory' CD4+ T-cells and T-cell receptor (TCR) V beta repertoire dynamics are independent of the levels of viremia following HIV seroconversion. Immunol Lett 1999 0.78
64 Neurophysiological assessment of peripheral nerve and spinal cord function in asymptomatic HIV-1 infection: results from the UCMSM/Medical Research Council neurology cohort. J Neurol 1995 0.77
65 Blood changes in experimental arthritis in two types of genetically different rats. Br J Pharmacol 1973 0.77
66 High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population. AIDS 1999 0.76
67 Differences between diurnal patterns of salivary cortisol and dehydroepiandrosterone in healthy female adolescents. Stress 2011 0.76
68 Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals. Antimicrob Agents Chemother 1996 0.75
69 HIV, AIDS, and zidovudine. Lancet 1992 0.75
70 Community-based respiratory viral infections in HIV positive patients with lower respiratory tract disease: a prospective bronchoscopic study. Genitourin Med 1996 0.75
71 HIV drug-resistance testing on archived samples to help current clinical decisions. AIDS 2000 0.75
72 Antiretroviral monotherapies and serum HIV-1 dynamics. Genitourin Med 1995 0.75
73 Transmission of HIV-1 infection by oroanal intercourse. Genitourin Med 1992 0.75
74 Sclerosing cholangitis rapidly following anti-HIV-1 seroconversion. Genitourin Med 1991 0.75
75 Changes in intravascular complement, kininogen, and histamine during Jarisch-Herxheimer reaction in secondary syphilis. Genitourin Med 1985 0.75
76 Detection of HIV-1 RNA in factor VIII concentrate. AIDS 1991 0.75
77 Lack of suppression by ribavirin of HIV viraemia. Lancet 1992 0.75
78 Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia. J Infect Dis 2001 0.75
79 Memory and learning in young adults with hydrocephalus and spina bifida: specific cognitive profiles. Eur J Pediatr Surg 2003 0.75
80 Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy. AIDS 2000 0.75
81 A pilot investigation into the neuroendocrine correlates of personality in the workplace. Percept Mot Skills 1998 0.75
82 A comparison of the hyperalgesic activity of some intravenous anaesthetics in mice. Arch Int Pharmacodyn Ther 1971 0.75
83 Desensitization of test anxious urban community-college students and resulting changes in grade point average: a replication. J Clin Psychol 1984 0.75
84 HIV suppression and risk of drug resistance mutations. AIDS 1998 0.75
85 Leucocyte ascorbate levels and postoperative deep venous thrombosis. Br J Surg 1979 0.75
86 Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. AIDS 1998 0.75
87 HIV-1 infection and cardiothoracic surgery: the difference in attitudes between consultants and junior surgeons in the United Kingdom. Eur J Cardiothorac Surg 1992 0.75